S&P Futures
4,036.75
+4.75(+0.12%)
Dow Futures
33,829.00
+6.00(+0.02%)
Nasdaq Futures
11,916.75
+43.50(+0.37%)
Russell 2000 Futures
1,900.80
+1.30(+0.07%)
Crude Oil
80.28
+0.13(+0.16%)
Gold
1,947.00
+4.40(+0.23%)
Silver
23.99
+0.04(+0.18%)
EUR/USD
1.0916
-0.0004(-0.03%)
10-Yr Bond
3.4620
-0.0070(-0.20%)
Vix
19.08
-0.12(-0.63%)
GBP/USD
1.2396
-0.0006(-0.05%)
USD/JPY
129.2760
-0.2330(-0.18%)
BTC-USD
23,189.43
+542.91(+2.40%)
CMC Crypto 200
527.10
+15.78(+3.09%)
FTSE 100
7,744.87
-12.49(-0.16%)
Nikkei 225
27,318.31
-76.70(-0.28%)
Investors did not like the latest update from Alzheimer's drug maker Cassava Sciences (NASDAQ:SAVA). After showing excellent results from the first 50 patients treated with simufilam, the company's prospective Alzheimer’s drug in an open-label